Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
CONCLUSIONS: Our buffy coat WTS data and plasma proteome data may serve as reliable sources for identifying etiology-specific blood biomarkers of HCC and might contribute to discovery of therapeutic targets for HCC across different etiologies.PMID:38486508 | DOI:10.3350/cmh.2024.0042 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 15, 2024 Category: Gastroenterology Authors: Jiwon Hong Jung Woo Eun Geum Ok Baek Jae Youn Cheong Seryoung Park Soon Sun Kim Hyo Jung Cho Su Bin Lim Source Type: research
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study
CONCLUSION: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.PMID:38468561 | DOI:10.3350/cmh.2023.0553 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Young Eun Chon Dong Yun Kim Mina Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Yeonjung Ha Joo Ho Lee Kwan Sik Lee Beodeul Kang Jung Sun Kim Hong Jae Chon Do Young Kim Source Type: research
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Clin Mol Hepatol. 2024 Jan 30. doi: 10.3350/cmh.2024.0028. Online ahead of print.NO ABSTRACTPMID:38471499 | DOI:10.3350/cmh.2024.0028 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Tsubasa Tsutsumi Dan Nakano Machiko Kawaguchi Hirokazu Takahashi Takumi Kawaguchi Source Type: research
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study
CONCLUSION: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.PMID:38468561 | DOI:10.3350/cmh.2023.0553 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Young Eun Chon Dong Yun Kim Mina Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Yeonjung Ha Joo Ho Lee Kwan Sik Lee Beodeul Kang Jung Sun Kim Hong Jae Chon Do Young Kim Source Type: research
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Clin Mol Hepatol. 2024 Jan 30. doi: 10.3350/cmh.2024.0028. Online ahead of print.NO ABSTRACTPMID:38471499 | DOI:10.3350/cmh.2024.0028 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Tsubasa Tsutsumi Dan Nakano Machiko Kawaguchi Hirokazu Takahashi Takumi Kawaguchi Source Type: research
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study
CONCLUSION: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.PMID:38468561 | DOI:10.3350/cmh.2023.0553 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Young Eun Chon Dong Yun Kim Mina Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Yeonjung Ha Joo Ho Lee Kwan Sik Lee Beodeul Kang Jung Sun Kim Hong Jae Chon Do Young Kim Source Type: research
JCAD, a new potential therapeutic target in cholestatic liver disease
Clin Mol Hepatol. 2024 Mar 8. doi: 10.3350/cmh.2024.0128. Online ahead of print.NO ABSTRACTPMID:38454802 | DOI:10.3350/cmh.2024.0128 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 8, 2024 Category: Gastroenterology Authors: Byoung Kuk Jang Source Type: research
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Clin Mol Hepatol. 2024 Mar 6. doi: 10.3350/cmh.2024.0157. Online ahead of print.NO ABSTRACTPMID:38447531 | DOI:10.3350/cmh.2024.0157 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 6, 2024 Category: Gastroenterology Authors: Hiroyuki Suzuki Tsubasa Tsutsumi Machiko Kawaguchi Keisuke Amano Takumi Kawaguchi Source Type: research
